Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Emvododstat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 5/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | ABCG2 | Q9UNQ0 | 9/20 | 0.58 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.58 |
| ▸ | KIF11 | P52732 | 5/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Emvododstat SCHEMBL9962251 | 1.00 | TP53 (0.62) | TP53MAPTSMN1; SMN2ABCG2ABCB1 | |
| Emvododstat SCHEMBL8509210 | 1.00 | TP53 (0.62) | TP53MAPTSMN1; SMN2ABCG2ABCB1 | |
| SCHEMBL15087042 | 1.00 | TP53 (0.62) | TP53MAPTSMN1; SMN2ABCG2ABCB1 | |
| Emvododstat SCHEMBL29965534 | 1.00 | TP53 (0.62) | TP53MAPTSMN1; SMN2ABCG2ABCB1 | |
| Emvododstat SCHEMBL29382728 | 1.00 | TP53 (0.62) | TP53MAPTSMN1; SMN2ABCG2ABCB1 | |
| SCHEMBL8403437 | 0.96 | TP53 (0.68) | TP53MAPTSMN1; SMN2ABCG2ABCB1 | |
| SCHEMBL11912892 | 0.95 | TP53 (0.60) | TP53MAPTSMN1; SMN2ABCG2ABCB1 | |
| SCHEMBL764818 | 0.95 | TP53 (0.60) | TP53MAPTSMN1; SMN2ABCG2ABCB1 | |
| SCHEMBL8402677 | 0.95 | TP53 (0.64) | TP53MAPTSMN1; SMN2ABCG2ABCB1 | |
| SCHEMBL9610871 | 0.95 | TP53 (0.60) | TP53MAPTSMN1; SMN2ABCG2ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100158858-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2010-06-24 | — | — | US | claimed |
| EP-2139476-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC Therapeutics, Inc. (US) | 2010-01-06 | — | — | EP | claimed |
| WO-2008127714-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | WO | claimed |
| WO-2008127715-A1 | CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | WO | claimed |
| US-10947231-B2 | Processes for the preparation of substituted tetrahydro beta-carbolines | PTC THERAPEUTICS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-10947231-B2 | Processes for the preparation of substituted tetrahydro beta-carbolines | PTC THERAPEUTICS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| WO-2020150326-A1 | METHOD FOR TREATING AN ACUTE MYELOID LEUKEMIA | PTC THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20190135810-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED TETRAHYDRO BETA-CARBOLINES | PTC THERAPEUTICS INC (US) | 2019-05-09 | — | — | US | disclosed |
| US-20190135810-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED TETRAHYDRO BETA-CARBOLINES | PTC THERAPEUTICS INC (US) | 2019-05-09 | — | — | US | disclosed |
| US-8703726-B2 | Methods for treating prostate conditions | PTC THERAPEUTICS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703726-B2 | Methods for treating prostate conditions | PTC THERAPEUTICS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20130171103-A1 | METHODS FOR TREATING VIRAL CONDITIONS | PTC THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| WO-2008127714-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080064683-A1 | Inhibition of VEGF Translation | PTC THERAPEUTICS, INC. | 2008-03-13 | — | — | US | disclosed |
| US-20080064683-A1 | Inhibition of VEGF Translation | PTC THERAPEUTICS, INC. | 2008-03-13 | — | — | US | disclosed |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | PCT THERAPEUTICS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | PCT THERAPEUTICS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070254878-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2007-11-01 | — | — | US | disclosed |
| US-20070254878-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2007-11-01 | — | — | US | disclosed |
| WO-2005089764-A9 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS INC (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947231-B2 | Processes for the preparation of substituted tetrahydro beta-carbolines | TPH1, TPH2, HTR1B | TP53 4291/4885MAPT 1457/4885SMN1; SMN2 1797/4885 |
| US-20100158858-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | RNMT, VEGFA, VHL | TP53 86/4885MAPT 3101/4885SMN1; SMN2 1436/4885 |
| US-20080064683-A1 | Inhibition of VEGF Translation | EIF4E, EIF4EBP1, VEGFA | TP53 854/4885MAPT 4518/4885SMN1; SMN2 4232/4885 |
| US-20070254878-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | VEGFA, FLT4, FLT1 | TP53 52/4885MAPT 3997/4885SMN1; SMN2 3261/4885 |
| US-20130171103-A1 | METHODS FOR TREATING VIRAL CONDITIONS | EIF2AK2, POLRMT, POLM | TP53 156/4885MAPT 2440/4885SMN1; SMN2 2448/4885 |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | VEGFA, FLT4, MIF | TP53 448/4885MAPT 2854/4885SMN1; SMN2 4645/4885 |
| US-20190135810-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED TETRAHYDRO BETA-CARBOLINES | TPH1, TPH2, HTR1B | TP53 4291/4885MAPT 1457/4885SMN1; SMN2 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.